• Survey by Wakefield Research and D-Wave shows 46% of surveyed business leaders expect $1 million to $5 million ROI from quantum optimization within the first year of adoption.
• 81% believe they have reached the limits of classical computing’s capabilities for optimization.
• 53% are planning to integrate quantum computing into their workflows, while 27% are considering it.
• Quantum optimization is seen as especially valuable in logistics, supply chain, manufacturing, planning and inventory, and R&D.
• 88% of participants said their organizations would “go above and beyond” for even a 5% improvement in optimization.

A new survey released by D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, suggests that quantum computing is gaining traction as a business tool, particularly for optimization problems. The findings point to a growing belief among surveyed decision-makers that classical computing may no longer be sufficient for the operational challenges they face (https://ibn.fm/YPAsc).

Conducted by Wakefield Research, the survey queried 400 business leaders from North America, Europe, and the Asia-Pacific region in May 2025. Respondents were decision-makers from industries such as logistics, manufacturing, life sciences, financial services, and retail; sectors where optimization is central to business success.

According to the study, 46% of respondents whose companies have already implemented quantum optimization or plan to do so within the next two years expect a return on investment of between $1 million and $5 million within the first 12 months. Another 27% predict a return of over $5 million during the same period.

A large majority of surveyed business leaders, 81%, believe they have reached the limits of what classical computing can deliver for optimization problems. These limitations appear to be pushing interest toward alternatives. Fifty-three percent of respondents reported they are planning to integrate quantum computing into their operational workflows, with another 27% considering doing so. 

The study highlights optimization as a focal point for quantum adoption. Key potential quantum optimization use cases cited include supply chain and logistics (50%), manufacturing (38%), planning and inventory (36%), and research and development (36%).

Importantly, 88% of participants said their organizations would “go above and beyond” for even a 5% improvement in optimization. This was especially true for participants in the manufacturing sector, where efficiency gains often translate directly to cost savings and margin improvements.

Companies continue to face hurdles when it comes to optimization. Respondents cited outdated technology (39%), budget constraints (38%), dependency on classical optimization on conventional computers (36%), and talent or skills shortages (35%) as key barriers. In addition, 87% acknowledged that internal complacency could be hindering innovation.

When asked about quantum’s usefulness in addressing specific operational problems, 60% of all respondents, and 73% of those most familiar with quantum optimization technology, said they expect it to be very or extremely helpful. Nearly a quarter in the latter group called quantum a “game changer” for their business operations.

According to D-Wave CEO Dr. Alan Baratz, the shift toward quantum optimization is no longer just about future potential—it’s about solving “business-critical problems now,” and this is something D-Wave is already doing with its quantum computing technologies. 

“Yesterday’s legacy computing solutions are struggling to keep pace with modern business,” said Dr. Baratz. “Leaders are increasingly recognizing that annealing quantum computing can play a pivotal role in solving business-critical problems now. This survey reflects the rapidly growing interest in applying quantum to complex optimization use cases, with business leaders unequivocally recognizing the substantial potential ROI of doing so.”

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. We are the world’s first commercial supplier of quantum computers, and the only company building both annealing and gate-model quantum computers. Our mission is to help customers realize the value of quantum, today. Our quantum computers — the world’s largest — feature QPUs with sub-second response times and can be deployed on-premises or accessed through our quantum cloud service, which offers 99.9% availability and uptime. More than 100 organizations trust D-Wave with their toughest computational challenges. With over 200 million problems submitted to our quantum systems to date, our customers apply our technology to address use cases spanning optimization, artificial intelligence, research and more. Learn more about realizing the value of quantum computing today and how we’re shaping the quantum-driven industrial and societal advancements of tomorrow: www.dwavequantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

• The trial targets never-smoker non-small cell lung cancer (“NSCLC”) patients, a group with limited treatment options.
• Japan’s high incidence of never-smoker NSCLC makes it a strategic region for the trial.
• LP-300 is being tested alongside standard chemotherapy agents in patients who have relapsed after tyrosine kinase inhibitor therapy.
• Lantern’s AI-driven approach may help identify and accelerate development of therapies in underserved cancer markets.
• Additional trial data from Taiwan and the U.S. is expected later in Q3 2025.

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, has completed targeted patient enrollment in Japan for its ongoing Phase 2 HARMONIC(TM) clinical trial evaluating investigational drug candidate LP-300 in never-smoker non-small cell lung cancer (“NSCLC”) patients (https://ibn.fm/JXFqG).

The company enrolled 10 patients across five sites in Japan, including the National Cancer Center in Tokyo, ahead of its internal timeline. The milestone underscores Lantern Pharma’s international strategy to focus on regions with a higher prevalence of never-smoker NSCLC cases, an under-addressed patient population with no approved treatments specifically targeting their form of lung cancer.

Lantern Pharma’s HARMONIC trial is evaluating LP-300 in combination with standard chemotherapy (carboplatin and pemetrexed) for patients who have previously relapsed after treatment with tyrosine kinase inhibitors (“TKIs”). The Japanese arm of the trial represents one part of a broader multinational study also enrolling patients in the United States and Taiwan.

Lantern Pharma CEO and President Panna Sharma described the enrollment success as a validation of the company’s focus on regions where never-smoker NSCLC is most prevalent. “Completing our targeted enrollment in Japan ahead of schedule demonstrates excellent execution of our international expansion strategy and validates our decision to focus on regions where never-smoker NSCLC has the highest prevalence,” said Sharma. “This achievement builds momentum as we continue enrollment in Taiwan and the United States, bringing us closer to generating the clinical data that could establish LP-300 as a treatment option for this underserved patient population with significant unmet medical need.”

In Japan, 33-40% of new NSCLC cases occur in never-smokers, a rate more than twice that of the U.S. or Europe, where the figure typically falls around 15%. In Taiwan, more than half of lung cancer cases are found in never-smokers. Lantern Pharma’s trial strategy is built around these regional disparities.

The HARMONIC trial is designed to enroll around 90 patients and includes overall survival (“OS”) and progression-free survival (“PFS”) as its primary endpoints. Initial results from a U.S. cohort showed an 86% clinical benefit rate and a 43% objective response rate among the first seven patients. One patient experienced a durable complete response in target cancer lesions, with survival now nearing two years (https://ibn.fm/5PJ3T).

LP-300, a disulfide small molecule, has a multimodal mechanism of action. It interacts with cell redox enzymes and modifies tyrosine kinase receptors, critical components in cancer cell growth and resistance pathways. The compound has already been tested in multiple Phase 1-3 trials involving over 1,000 subjects, with retrospective analyses suggesting a survival advantage in never-smoker lung adenocarcinoma patients.

No therapies are currently approved specifically for never-smoker NSCLC. This makes Lantern’s work in this space a potentially valuable asset in the oncology drug development market. The company estimates the global market opportunity for treating never-smoker NSCLC exceeds $4 billion annually.

The potential value is compounded by Lantern Pharma’s AI-driven drug development platform, RADR(R). The platform analyzes large volumes of oncology data, more than 100 billion data points and 200+ machine learning algorithms, to identify molecular targets, refine trial design, and reduce the time and cost of oncology drug development. The company’s pipeline includes other AI-discovered or AI-enhanced oncology candidates. In March 2024, Lantern dosed patients in a Phase 1a/1b trial for LP-284, an agent targeting relapsed or refractory non-Hodgkin’s lymphoma.

Lantern Pharma has signaled openness to partnership or licensing discussions for LP-300 to support commercialization across different geographies. The company expects to provide additional trial updates, including data from Taiwan and the U.S., before the end of the third quarter of 2025.

For more information, visit the company’s website at www.LanternPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN

• Lantern Pharma has introduced an AI-powered module within its RADR(R) platform to assess DDA-DDRi combination therapies.
• The module uses genomic, transcriptomic, and clinical data, to predict treatment synergy and patient response, and supported the design of Lantern’s FDA-cleared Phase 1B/2 trial in triple-negative breast cancer.
• A review of 221 clinical trials informed the development of the predictive algorithm.
• Non-PARP DDRi combinations with DNA-damaging agents showed strong outcomes in specific cancer subtypes.
• Lantern is evaluating licensing opportunities to commercialize the module for broader oncology use.

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, has unveiled a new artificial intelligence module designed to predict the effectiveness of cancer treatment combinations involving DNA-damaging agents (“DDAs”) and DNA damage response inhibitors (“DDRis”). The technology is integrated into the company’s RADR(R) platform, which supports AI-guided drug development.

The launch comes at a time when the global market for combination cancer therapies is projected to surpass $50 billion by 2030, according to Lantern’s announcement (https://ibn.fm/3ZspZ).

The new module draws on multi-omics data – genomic, transcriptomic, and clinical –and applies machine learning models to predict which DDA-DDRi combinations are likely to produce synergistic effects in specific patient subgroups. Lantern says this approach can help design more effective, less toxic treatments and reduce development timelines and costs by up to one-third.

Panna Sharma, Lantern’s CEO and president, said the AI module aims to streamline the development of tailored cancer therapies. “This AI-powered module is a transformative step in our mission to deliver personalized cancer treatments,” said Sharma. “By leveraging our RADR(R) platform to analyze complex multi-omics and clinical trial data, we identified optimal DDA-DDRi combinations that guided the development of our TNBC trial. We believe this approach could reduce combination therapy development timelines and costs by one-third compared to traditional methods.”

The system’s predictive capabilities are underpinned by a peer-reviewed study published in Frontiers in Oncology that examined 221 clinical trials involving DDA-DDRi regimens (https://ibn.fm/MvmkB). From these, 89 trials with interpretable outcomes were scored based on effectiveness, safety, and biomarker-driven responses. This data was then used to train the AI model, which classifies agents into 8 DDA and 14 DDRi subclasses.

Among the study’s findings, non-PARP DDRi combinations, especially those involving WEE1 inhibitors like adavosertib paired with platinum agents, showed an 80% positive outcome rate in interstrand cross-linker trials. This approach may hold particular promise for cancers with TP53 mutations, which are often difficult to treat.

The module also highlights how biomarker profiling can improve patient selection. For example, TP53 mutations and homologous recombination deficiency (“HRD”) signatures emerged as key predictors of drug response. In some regimens, reformulated drugs helped reduce toxicity. Liposomal doxorubicin, a variant with lower cardiotoxicity, was identified as a safer option for combination strategies.

Lantern has already applied the module’s insights to the design of its current clinical programs. Notably, the RADR(R) platform informed the company’s FDA-cleared Phase 1B/2 trial testing LP-184 and olaparib in triple-negative breast cancer (“TNBC”), a subtype with limited treatment options and high unmet need.

According to the company, the AI module’s architecture includes multiple specialized agents that aggregate data, classify compounds, identify biomarkers, and model outcomes. Its design allows it to evolve with new inputs, making it a continuously learning system.

Lantern is also exploring potential licensing agreements to bring the tool to a broader range of research institutions and biotech firms. The company believes the AI module could accelerate the pace of combination therapy development across various cancer types.

By embedding this technology into RADR(R), Lantern Pharma continues to position itself as a developer of data-driven approaches to oncology drug development. The module not only improves the chances of clinical success but also aligns with growing industry efforts to personalize cancer treatments based on molecular and genetic profiles.

For more information, visit the company’s website at www.LanternPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN

• The FDA-cleared HeartBeam system enables patients and physicians to access significant arrhythmia data outside traditional clinical settings.
• The HeartBeam system, credit card–sized and fully portable, represents a breakthrough in ambulatory cardiac care. 
• Beyond ambulatory arrhythmia assessment, the platform is poised for future advancements, including synthesized 12-lead ECG generation.

Foundational clearance from the U.S. Food and Drug Administration (“FDA”) for its patented HeartBeam system has proved pivotal for HeartBeam (NASDAQ: BEAT), a cardiac technology company focused on transforming the cardiac-care space (https://ibn.fm/0TAG4). The first cable-free, high-fidelity ECG device that captures the heart’s electrical activity from three distinct directions, the HeartBeam system enables patients and physicians to access critical arrhythmia data outside traditional clinical settings.

The HeartBeam system, credit card–sized and fully portable, represents a breakthrough in ambulatory cardiac care. The device, which is equipped with five electrodes and records three-directional electrical signals over a 30-second period, is the first of its kind to receive FDA clearance in December 2024. When a patient experiences symptoms, the accompanying smartphone app walks them through capturing a recording. The recorded data is transmitted via the cloud, reviewed by a physician within the context of symptoms and medical history, and used to direct timely care. This capability significantly reduces diagnostic delays and enables proactive management of arrhythmias.

“It’s well documented that patients who delay seeking care for their cardiac symptoms face worse clinical outcomes,” said HeartBeam CEO Robert Eno. “The ability for patients to capture high-fidelity ECG signals from three distinct directions wherever they are when symptoms occur will help patients get the care they need in a timelier manner. The foundational FDA clearance of our technology for arrhythmia assessment is a significant milestone for the company that brings us one step closer to fulfilling our vision of providing unprecedented cardiac insights to individuals and physicians.”

According to the company, the initial clearance paves the way for HeartBeam to initiate an Early Access Program, allowing patients and physicians to evaluate the system ahead of its commercial launch. This program is designed to refine user experience and workflow while providing real-world feedback ahead of broader market entry.

Beyond ambulatory arrhythmia assessment, the platform is poised for future advancements, including synthesized 12-lead ECG generation. HeartBeam’s proprietary personalized transformation matrix allows the system to convert the three-directional signals into a synthesized 12-lead ECG, a feature that is expected to provide access to actionable information, enabling physicians to direct patients to timely, appropriate care. The 12-lead ECG synthesis software is currently under FDA review with clearance anticipated later this year.

The company is also developing AI-powered algorithms to enhance arrhythmia detection; early data suggests promising improvements in identifying atrial flutter and other rhythm disturbances, with performance in some cases surpassing cardiologists. HeartBeam plans to submit its AI algorithms for FDA clearance in the future. 

HeartBeam’s technology is underpinned by a robust intellectual property portfolio, which now includes more than 20 issued U.S. and international patents, as well as 2 allowed patents and 32 pending patents (https://ibn.fm/JT9mB). HeartBeam is now building upon the FDA clearance, with a clear runway toward commercial deployment in arrhythmia diagnostics and beyond.

As HeartBeam progresses toward broader clinical adoption, its focus remains on integrating patient-generated ECG data into daily care pathways. Remote monitoring and telehealth platforms stand to benefit from this innovation, particularly in managing chronic cardiac conditions and minimizing hospital readmissions. HeartBeam’s technology aligns with the growing movement toward decentralized, intelligent diagnostics.

With the foundational FDA clearance secured, HeartBeam plans to expand access through early access programs, deploy field-testing among medical practices and ultimately commercialize the system. The anticipated sequence of steps includes physician training, system support and data collection to streamline regulatory and commercial readiness. With a transformative roadmap in place, HeartBeam is positioned to redefine the future of cardiac care, taking it outside the hospital and putting it into the hands of patients and clinicians alike.

For more information, visit HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

• Drug delivery plays a critical role in modern healthcare, but when it comes to potent opioids such as fentanyl, the stakes are particularly high
• Nutriband is developing Aversa(TM), a proprietary abuse-deterrent transdermal technology designed to prevent diversion, misuse, abuse and accidental exposure
• Nutriband’s Aversa(TM) fentanyl patch is estimated to have a market potential of $80 million to $200 million annually within five years of launch  

Developing safe, effective and abuse-deterrent delivery systems for controlled substances such as fentanyl is a formidable challenge, and Nutriband (NASDAQ: NTRB) is positioning itself at the forefront of that effort. The company is pioneering transdermal technologies to deliver medications that require careful balancing of patient access with strong mitigation against misuse.

Drug delivery plays a critical role in modern healthcare, but when it comes to potent opioids such as fentanyl, the stakes are particularly high. Fentanyl is approximately 50 times more potent than heroin, and even trace amounts can be fatal, making it a dangerous ingredient when diverted or misused (ibn.fm/0eIOJ). Traditional opioid formulations, including extended-release patches and pills, have frequently been targets for tampering and abuse, leading the FDA to mandate risk management programs and abuse-deterrent formulations (“ADF”) that can help reduce misuse without compromising legitimate patient care (ibn.fm/hgJ0P).

The central difficulty lies in achieving the delicate balance: preventing abuse while preserving patient access for those legitimately in need. Abuse-deterrent technologies are designed to thwart crushing, dissolving or extracting the active drug for illicit use, particularly via injection or snorting. While they cannot eliminate all forms of misuse, they serve as a vital tool in limiting harm and encouraging safe use under medical supervision.

Healthcare providers and regulators like note that ADFs must be combined with comprehensive strategies including monitoring, prescribing oversight and patient education. For drug developers, creating a delivery platform that ensures therapeutic efficacy without enabling tampering is a complex scientific and regulatory challenge. Formulation must be stable, bioavailable and amenable to large-scale manufacturing while reliably deterring common abuse modes.

This is where Nutriband enters the scene. Nutriband is developing Aversa(TM), a proprietary abuse-deterrent transdermal technology designed to prevent diversion, misuse, abuse and accidental exposure. Applied as a coating on fentanyl patches, Aversa introduces aversive agents that discourage tampering and unauthorized use while maintaining steady, controlled delivery for pain patients (ibn.fm/stX9e). The strategy supports patient access by enabling effective chronic pain management with lower systemic exposure and sustained-release characteristics.

Nutriband is collaborating with Kindeva Drug Delivery to manufacture its AVERSA(TM) fentanyl patch. Kindeva has validated that this aversive coating can be applied using standard commercial transdermal production methods, a major step toward scale-up and regulatory compliance (ibn.fm/c6tua). Notably, the FDA’s 505(b)(2) regulatory pathway may allow Nutriband to rely significantly on existing safety and efficacy data for fentanyl patches, potentially reducing the need for extensive phase 2 and 3 trials and accelerating market access (ibn.fm/9ihPI).

The broader impact is significant. Nutriband’s leadership recognizes that fentanyl misuse remains a top contributor to opioid-related overdose deaths. By embedding abuse deterrence in a transdermal format, the company offers an option aiming to deliver pain relief responsibly. Nutriband’s Aversa fentanyl patch is estimated to have a market potential of $80 million to $200 million annually within five years of launch (ibn.fm/r7FtN), a forecast that reflects real need among practitioners seeking safer prescribing alternatives.

Beyond fentanyl, Nutriband’s transdermal platform has broader applicability. Its clinical subsidiary, 4P Therapeutics, is working on formulations for buprenorphine, methylphenidate, peptides, and biologics — all candidates for safe, patch-based delivery. This positions Nutriband to leverage its transdermal expertise across multiple therapeutic areas, potentially transforming how many medications are administered, and how patients adhere to treatment.

Nutriband’s efforts illustrate the significant role that drug-delivery innovation plays in today’s pharmaceutical landscape. By integrating abuse-deterrent strategies into transdermal platforms, Nutriband seeks to improve outcomes for chronic pain patients and reduce the societal burden of opioid misuse, a challenging but potentially transformative contribution to public health. 

For more information, visit the company’s website at www.Nutriband.com.

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

• Mullen Automotive recently brought all of its EV products and brands together under one strong and unified identity — Bollinger Innovations.
• The pivot to one commercial EV brand comes amid mounting demand for electrification in delivery, logistics and municipal vehicle fleets.
• The company’s new identity is also trading under new Nasdaq stock symbol NASDAQ: BINI.
• The company’s move under one brand clarifies market positioning, creating cohesion across product lines ready to service the commercial vehicle industry.

Bollinger Innovations (NASDAQ: BINI), formerly known as Mullen Automotive, has completed a major corporate transformation, officially rebranding and switching its NASDAQ ticker from MULN to BINI (https://ibn.fm/2bEWf). The updated identity aligns the company’s commercial electric vehicle (“EV”) offerings, including its Class 1 cargo van and Class 3 and 4 cab chassis trucks, under the unified Bollinger brand and emphasizes its commitment to serving the U.S. commercial mobility market with domestically manufactured EVs.

Bollinger Innovations is building the next-generation commercial EVs in Tunica, Mississippi, offering California Air Resources Board (“CARB”) and EPA certified models: the Urban Delivery ONE EV cargo van (Class 1), the Urban Utility THREE EV cab chassis truck (Class 3) and the Bollinger B4 all-electric cab chassis truck (Class 4). These commercial EVs are available for purchase throughout the United States.

“Our transition to Bollinger Innovation goes beyond a simple name change,” said CEO and chairman David Michery. “We are bringing our products and brands together under one strong and unified identity, ready to service the commercial vehicle industry.”

The pivot toward commercial EVs comes amid mounting demand for electrification in delivery, logistics and municipal vehicle fleets. While passenger EV sales rose sharply, with global electric car sales expected to exceed 20 million units in 2025 and more than 20% market share (https://ibn.fm/XqmoM), commercial EV adoption remains nascent, accounting for an estimated 2% of U.S. commercial vehicle sales as of 2023 (https://ibn.fm/MynoT). Industry sources estimate that commercial fleets contribute disproportionately to urban emissions, and electrification is seen as essential to meeting decarbonization targets.

U.S. automakers are accelerating domestic EV production: In Detroit, GM recently pledged $4 billion toward U.S. manufacturing expansion through 2027, including EV assembly at Factory ZERO and new battery facilities (https://ibn.fm/aKKeb). The United States remains a net importer of electric cars and trucks, highlighting both vulnerability and opportunity in domestic supply chain reshoring (https://ibn.fm/3tJe8). With this in mind, Bollinger Innovations’ control over its commercial EVs, certification and U.S.-based production positions it to compete directly in strategic fleet electrification initiatives.

The company’s new identity consolidates all commercial vehicle lines under one brand, clarifying market positioning and creating operational cohesion across product lines. Though stockholders were not required to take any action, the rebranding signals an important turning point, from a broader EV vision under Mullen to a focused execution on Class 1, 3 and 4 commercial platforms built in America. Bollinger’s models are positioned for use by last mile delivery firms, municipal fleets and specialist vocational upfitters, aligning with increasing standards for zero-emission vehicles in cities and states.

Commercial EV sales in the United States are forecast to scale rapidly, driven by policy mandates, corporate ESG targets and rising consumer expectation, which creates a significant addressable market for Bollinger. While commercial EVs remain just over 2% of the U.S. market currently, they are expected to grow sharply in coming years to reach parity with passenger EV expansion trends (Rabobank). For Bollinger, with vehicles already CARB and EPA certified and ready for deployment, the potential opportunity in fleet electrification is immediate and backed by American-made manufacturing that could qualify for incentives under IRA domestic content rules.

The rebrand also follows a complex corporate history. Mullen acquired controlling interest in Bollinger Motors in 2022, retaining and integrating Bollinger’s commercial platform and dealer network, which now comprises more than 50 dealer locations across the country and supports the company’s entry into commercial EV sales. This strategic continuity underscores the company’s long-term commitment to delivering commercial EVs at scale.

Bollinger Innovations enters the next phase with full U.S. assembly, certified products and a clear brand narrative grounded in commercial fleet electrification. With growing regulatory momentum behind domestic EV manufacturing and heavy-duty vehicle electrification, the company’s timing appears well-aligned with national infrastructure goals.

For more information, visit www.BollingerEV.com.

NOTE TO INVESTORS: The latest news and updates relating to BINI are available in the company’s newsroom at https://ibn.fm/BINI

• Two newly issued patents mark a strategic advancement in HeartBeam’s proprietary technology.
• The first patent protects the company’s credit card–sized, cable-free 3D ECG device designed to capture high-fidelity electrical signals from three noncoplanar directions.
• The second patent covers the company’s rhythm analysis algorithm by continuously analyzing signal input.

HeartBeam (NASDAQ: BEAT), a cardiac technology company, has secured two new U.S. patents that significantly enhance its intellectual property portfolio and strengthen its position in cardiac monitoring technology (https://ibn.fm/6xni4). The company, focused on delivering powerful, personalized insights into heart health through its innovative 3D ECG platform, now holds more than 20 U.S. and international patents, with additional applications pending.

The newly issued patents mark a strategic advancement in HeartBeam’s proprietary technology. The first patent protects the company’s credit card–sized, cable-free 3D ECG device designed to capture high-fidelity electrical signals from chest and finger electrodes in three noncoplanar directions. This portable device enables users to record their cardiac symptoms in real-time and synthesizes the recordings into a familiar 12-lead ECG reading through a personalized transformational matrix. The 12-led ECG synthesis software is now under FDA review, supported by data from the VALID-ECG pivotal study (https://ibn.fm/flaAR).

The second patent covers the company’s rhythm analysis algorithm, which classifies heart rhythms such as sinus rhythm, atrial fibrillation and other arrhythmias, by continuously analyzing signal input. Designed for integration with any cardiac monitoring system, including wearables, it provides on-device, risk-based escalation by detecting anomalies and prompting users to record high-fidelity 3D ECG signals for 12-lead synthesis. HeartBeam plans to submit the rhythm analysis algorithm for FDA clearance in the future.

“HeartBeam’s vision is to make it easier for patients and physicians to monitor and diagnose cardiac symptoms outside of a medical facility,” said HeartBeam CEO Robert Eno. “The new patents add to our growing IP portfolio, enabling us to expand the reach and impact of our groundbreaking 3D ECG technology as we strive to transform the future of cardiac care.”

These patents significantly bolster the defensive moat around HeartBeam’s core technology, enabling future product extensions in areas such as AI-driven arrhythmia classification and ischemia detection. Their addition brings the company’s IP holdings to more than 20 issued U.S. and international patents, 2 allowed patents and 32 pending applications.

BEAT’s platform centers on its proprietary 3D ECG technology, which collects the heart’s electrical signals in three distinct noncoplanar directions and transforms those signals into synthesized 12-lead ECGs. This platform technology is designed for use in a range of form factors, including credit card–sized monitors, extended-wear patches and wrist-worn devices. This transformative approach empowers physicians to monitor patients remotely and direct them to appropriate care outside traditional medical facilities.

HeartBeam’s broadened patent portfolio may strengthen investor confidence by positioning the company securely in a highly competitive medical device landscape. A robust IP framework is a critical asset in the system of portable devices aimed at transforming cardiac care delivery. As HeartBeam moves toward broader clinical adoption and regulatory milestones, the two newly issued patents offer added protection and commercialization leverage. They lay the groundwork for future enhancements while strengthening partnerships and facilitating market access.

For more information, visit HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

• Recent White House announcements with EU and Japan outline tariff guidelines, investment commitments.
• The confluence of trade policy and industrial investment creates a strategic trade windfall for U.S. critical minerals. 
• Ucore’s proprietary RapidSX technology offers a compelling supply chain solution.

Recent trade agreements with the European Union and Japan are unlocking massive investment that could reshape U.S. manufacturing, particularly for critical components such as permanent magnet materials. Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) and its RapidSX(TM) separation technology are strategically positioned to become the North American gatekeeper for magnet-grade rare earth oxides under this new industrial paradigm.

Under President Donald Trump’s newly negotiated framework with the EU, a baseline 15% tariff applies to most imports, but the EU also pledged up to $1.15 trillion in investment and U.S. energy purchases by 2028 (https://ibn.fm/zY7Ph). A similar pact with Japan sets comparable tariffs and commits $550 billion in investment back into the U.S. economy (https://ibn.fm/Cizj2). These moves are designed to accelerate domestic production in sectors such as electric vehicles (“EVs”), wind turbines and defense systems.

While higher import duties shield domestic industry, the accompanying capital inflow is drawing OEMs to scale operations stateside, but they now urgently require a homegrown source of reliable heavy rare earth elements (“HREE”). This is where Ucore’s proprietary RapidSX technology offers a compelling supply chain solution. RapidSX can separate HREE oxides about three times faster than conventional solvent extraction and uses only one-third the physical footprint (https://ibn.fm/aCYgH). Ucore’s Louisiana Strategic Metals Complex (“SMC”) in Alexandria is slated to begin commercial feedstock production in 2026, supplying magnet-grade neodymium, praseodymium, terbium and dysprosium, all tariff-insulated by virtue of onshore U.S. production.

Meanwhile, Ucore’s RapidSX demonstration facility in Kingston, Ontario, has already completed commissioning and is actively processing multiple feedstock sources for OEM qualification (https://ibn.fm/BGFhM). The Kingston plant is critical in de-risking scale-up by producing sample batches for metalizers and alloy companies. This gives EU and Japanese investors seeking near-term, tariff-free supply chains a tangible asset in the rare earth supply equation, anchored by RapidSX’s ability to deliver purity at speed with minimal environmental impact.

The confluence of trade policy and industrial investment creates a strategic trade windfall for U.S. critical minerals. With $1.15 trillion in EU commitments and $550 billion from Japan coalescing under the new tariffs framework, domestic OEMs in EV and renewable energy sectors are compelled to localize magnet material sourcing. Ucore is ready to meet that demand, delivering high-grade REE feedstock from its Louisiana SMC, powered by RapidSX technology that offers superior throughput, smaller environmental footprint and faster implementation.

Beyond its industrial advantage, Ucore has aligned federal and defense interest behind its plans. The U.S. Department of Defense previously awarded phase 2 project funding totaling $18.4 million for construction and equipment procurement for the Louisiana SMC, a testament to the technology’s importance to national security supply chains. Ucore’s public groundbreaking earlier this year drew in support from Louisiana state authorities, regional economic development groups and the DoD, underscoring the facility’s role as a strategic hub in the domestic rare-earth ecosystem (https://ibn.fm/7I0t5).

With the demonstration plant de-risking feedstock and OEM qualifications already underway, Ucore is positioned not only as an REE separator but as a strategic industrial partner in rebuilding North American critical minerals independence at the nexus of trade policy, clean tech demand and defense security.

For more information, visit www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• AI Maverick’s next-gen platform can replicate human-like sales conversations—handling prospecting, objections, and scheduling with no SDR required
• Recent rollout includes adaptive language models, real-time buying signal detection, and multi-step consultative selling automation
• Company rebrand reflects shift from biotech to AI-led customer acquisition across sectors like healthcare, transportation, and insurance

In a world where sales teams are expected to scale faster than ever, often with fewer resources, the rise of intelligent automation platforms is beginning to redefine how companies engage with prospects. For years, sales development representatives (“SDRs”) have filled the gap between marketing and revenue, conducting outreach, asking discovery questions, and teeing up calls for closers. But as labor shortages, high turnover, and inconsistent outreach quality plague well-funded organizations, a new breed of AI solutions is emerging to address these challenges head-on.

Rather than merely generating leads or surfacing intent signals, today’s most advanced AI platforms are starting to simulate the entire early-stage sales process: researching contacts, reaching out on the right channel at the right time, and responding in real-time with human-quality dialogue. These tools aren’t science fiction; they’re being deployed now. One of the companies leading this transformation is AI Maverick Intel (OTCID: BINP).

From Pharma Roots to AI-Led Sales Automation

Formerly known as Bionoid Pharma Inc., the company officially rebranded as AI Maverick Intel in May 2025, reflecting a strategic shift away from biotech and toward artificial intelligence-powered business solutions. The pivot coincided with the acquisition of a proprietary AI engagement platform, also called AI Maverick, that now serves as the company’s core offering.

CEO Wayne Cockburn noted that the rebrand was not just a name change but a full transformation in mission, “Our evolution into AI Maverick Intel, Inc. signifies our dedication to pioneering AI technologies that drive meaningful engagement and sustainable growth.”

The company’s platform, which leverages intelligent two-way communication, enables clients to acquire customers with far greater efficiency. It’s already seeing traction in high-touch verticals such as healthcare, insurance, transportation, and biotech, sectors where early outreach has traditionally required specialized, trained reps.

By eliminating traditional friction in the outreach process, AI Maverick Intel empowers organizations to connect with target audiences at scale. Its automation-first model positions the company to capitalize on the growing AI-in-marketing sector, which is projected to reach $82.23 billion by 2030. With intelligent engagement at its core, AI Maverick is redefining how businesses build relationships, drive growth, and unlock value across the customer lifecycle.

The New Prospecting Engine: Built for Scale, Without the Headcount

In its most significant update to date, AI Maverick Intel launched a next-generation prospecting engine in July 2025, designed to eliminate the need for SDR teams altogether. The release is more than a tool; it’s a comprehensive suite capable of replicating entire segments of the sales pipeline.

Key features include:

• Comprehensive contact intelligence – Merging structured and unstructured data to build rich contact profiles that include job changes, buying signals, and preferences
• Context-aware outreach – Language models that tailor timing, tone, and channel for each interaction, allowing the system to manage both transactional and consultative outreach
• Conversational handling – Built-in responses for objections, follow-up questions, and meeting scheduling

This approach moves beyond typical automation tools. “By managing discovery questions, objections, and next-step scheduling, the platform now addresses the consultative side of selling,” Cockburn explained. “In industries where meaningful conversations are critical, automating those interactions can accelerate deal flow and reduce acquisition costs.”

Replicating the Human Sales Funnel, End-to-End

What sets AI Maverick apart is its ability to serve both transactional and relationship-driven sales motions. The platform is equipped to handle:

• Transactional sales, such as renewals, reorders, or quick quote generation, entirely through AI
• Consultative sales, involving multi-step dialogues, tailored recommendations, and needs analysis

The AI is trained not just to send messages but to carry out actual conversations that would traditionally require an experienced sales rep. And with deployment times reportedly under one business day, companies can begin realizing ROI almost immediately.

Name Change Finalized, New Identity Taking Shape

The transformation is now formalized on paper as well. As of late May, Delaware approved the company’s name change from Bionoid Pharma Inc. to AI Maverick Intel, Inc., and the company has filed the necessary paperwork with FINRA for a ticker update. Once approved, the OTC Markets will reflect the new name and direction, aligning its public market identity with its operational focus.

Cockburn noted, “This milestone moves us one step closer to fully implementing the AI Maverick vision. We’re unlocking new opportunities to scale our platform and partner with innovators across AI, biotech, and digital health.”

Positioned for the AI-Led Future of Revenue Ops

The timing for AI Maverick’s strategic repositioning couldn’t be more relevant. As companies reevaluate how they allocate headcount and budget for customer acquisition, the demand for scalable, AI-powered outreach is only rising. With its fully developed platform, AI Maverick is targeting a multi-billion-dollar opportunity in sales tech, especially within verticals underserved by traditional CRMs or outreach platforms.

Moreover, AI Maverick’s value proposition, automating meaningful sales conversations without human reps, offers not just cost savings, but the possibility of scaling revenue pipelines far faster than traditional hiring allows.

As more companies explore whether AI cannot just assist, but replace portions of their sales process, AI Maverick Intel is already operating in that future.

For more information, visit www.AIMaverickIntel.com.

NOTE TO INVESTORS: The latest news and updates relating to BINP are available in the company’s newsroom at ibn.fm/BINP

• FDA approval is a powerful inflection point in the lifecycle of any biopharmaceutical company 
• Nutriband’s recent 25% preferred stock dividend uniquely ties shareholder reward to regulatory achievement
• CEO notes that “core goal is to continue to create value for our shareholders particularly as we near closer to the commercialization of AVERSA(TM) Fentanyl”

Obtaining approval from the U.S. Food and Drug Administration (“FDA”) is a monumental achievement for any biopharmaceutical company, serving as a critical validation of a drug’s safety and efficacy. This rigorous process is a cornerstone of public health, ensuring that only treatments proven to be beneficial and with acceptable risks reach patients. Recognizing the immense value this milestone represents, Nutriband (NASDAQ: NTRB) recently underscored its commitment to this pathway by announcing a 25% preferred stock dividend as the company targets filing for FDA approval for its lead product, AVERSA(TM) Fentanyl (https://ibn.fm/8FRUA).

FDA approval is a powerful inflection point in the lifecycle of any biopharmaceutical company. Recent research published in “Drug Discovery Today” examined biotech firms that received FDA Fast Track designation between 2019 and 2020 and found average cumulative abnormal returns (“CAR”) of 21.6% over five days, 38.3% over 30 days, 76.6% after one year, and an impressive 111% over three years, highlighting the long-term investor confidence triggered by regulatory milestones (https://ibn.fm/L51Jp).

Approval not only unlocks revenue streams, but it also legitimizes a company’s technology in the eyes of regulators, insurers and prescribers and can play a crucial role in facilitating downstream opportunities such as commercial manufacturing partnerships and product integration into healthcare systems. For Nutriband, whose Aversa technology integrates aversive agents into fentanyl patches to deter abuse, approval is indispensable for scaling manufacturing agreements, similar to the one it currently has with Kindeva Drug Delivery (https://ibn.fm/3YRfX), and executing its business plan. Additionally, approved status is often the trigger for a variety of financing mechanisms, from venture rounds to licensing deals. offering new capital and strategic flexibility. 

Nutriband’s recent 25% preferred stock dividend — one preferred share for every four common shares held, with a record date of July 25 and payment scheduled for August 5 — uniquely ties shareholder reward to regulatory achievement. These preferred shares will automatically convert into common stock upon FDA approval of Aversa. If not converted, they will yield annual cash dividends tied to company profitability, reinforcing Nutriband’s pledge to distributor shareholder value. 

“Our core goal is to continue to create value for our shareholders particularly as we near closer to the commercialization of AVERSA(TM) Fentanyl,” said Nutriband CEO Gareth Sheridan. “We recently highlighted our commercialization manufacturing process scale up with Kindeva, and we are now laser focused on finalizing our development pathway to FDA approval.”

Founded with a focus on abuse-deterrent transdermal patches, Nutriband has progressed major milestones swiftly. The company’s Aversa patch incorporates aversive agents into fentanyl patches to prevent misuse and accidental exposure. The company has built a global IP protection strategy, securing patents across the United States, Europe, Asia and Australia. With commercialization manufacturing scaled up in collaboration with Kindeva, Nutriband is poised for submission to the FDA, potentially initiating a transition that would unlock major revenue opportunities. A preferred dividend tied to FDA approval crystallizes the company’s dual aim: incentivize shareholders now while targeting near-term regulatory proof points.

With its innovative technology, robust IP, scaled manufacturing plan and shareholder-friendly dividend structure, Nutriband is crafting a compelling narrative for the biotech world —and Wall Street. As other biotechs recalibrate their financial structures to support milestone-focused value delivery, Nutriband has taken an early lead. 

For more information, visit the company’s website at www.Nutriband.com.

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB